

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent:	MOLT-4 Cells (8)
Catalog Number:	175
Lot Number:	140078
Release Category:	C
Provided:	4.40 x 10 ⁶ cells/vial. Viability, 49%.
Cell Type:	Mature T-lymphoblast
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%.
Growth Characteristics:	Cells grow as a suspension. Maintain cells at 3 x 10^5 /ml. Split twice a week 1:4 to 1:5.
Sterility:	Negative for mycoplasma, bacteria and fungi.
Description:	Originally derived from the peripheral blood of a 19-year-old male with acute lymphoblastic leukemia in relapse. Clone 8 was obtained by subcloning in soft agarose by Kikukawa et al.
Special Characteristics:	Highly susceptible to HTLV-III. Following infection, CPE is observed after one day, and giant cells after five days. Can be used to isolate and continuously produce SIV agm virus (cat# 174).
	Alternate names: MOLT-4 clone 8
Recommended Storage:	Liquid nitrogen.
Contributor:	Dr. Ronald Desrosiers

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:	Daniel MD, Li Y, Naidu YM, Durda PJ, Schmidt DK, Troup CD, Silva DP, MacKey JJ, Kestler HW III, Sehgal PK, King NW, Ohta Y, Hayami M, Desrosiers RC. Simian immunodeficiency virus from African green monkeys. <i>J Virol</i> 62 :4123-4128, 1988.
	Kikukawa R, Koyanagi Y, Harada S, Kobayashi N, Hatanaka M, Yamamoto N. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. <i>J Virol</i> 57 :1159-1162, 1986.
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Molt-4 Clone 8 from Dr. Ronald Desrosiers." Also include the references cited above in any publications.
	Available only for non-commercial use. Requests from commercial organizations should be directed to Harvard Medical School Office of Technology Development at the following email address: <u>hms_materialtransfer@harvard.edu</u> .
Last Updated	May 10, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.